CIVALLERO, Monica
 Distribuzione geografica
Continente #
NA - Nord America 4.790
AS - Asia 1.767
EU - Europa 1.590
SA - Sud America 269
AF - Africa 63
Continente sconosciuto - Info sul continente non disponibili 59
OC - Oceania 4
Totale 8.542
Nazione #
US - Stati Uniti d'America 4.655
SG - Singapore 526
CN - Cina 467
GB - Regno Unito 444
IT - Italia 383
VN - Vietnam 206
HK - Hong Kong 204
BR - Brasile 191
SE - Svezia 155
DE - Germania 132
RU - Federazione Russa 94
BD - Bangladesh 85
FI - Finlandia 82
UA - Ucraina 66
FR - Francia 65
CA - Canada 55
TR - Turchia 53
KR - Corea 37
IN - India 32
IE - Irlanda 29
ID - Indonesia 28
JP - Giappone 26
BG - Bulgaria 24
AR - Argentina 22
MA - Marocco 19
NL - Olanda 19
BE - Belgio 18
MX - Messico 18
IQ - Iraq 16
ZA - Sudafrica 16
EC - Ecuador 15
MY - Malesia 12
PR - Porto Rico 12
ES - Italia 11
GP - Guadalupe 11
CL - Cile 10
LT - Lituania 10
PK - Pakistan 10
PL - Polonia 10
IL - Israele 9
PE - Perù 9
SV - El Salvador 9
AT - Austria 8
SA - Arabia Saudita 8
EG - Egitto 7
LB - Libano 7
VE - Venezuela 7
AE - Emirati Arabi Uniti 6
CH - Svizzera 6
CR - Costa Rica 5
CW - ???statistics.table.value.countryCode.CW??? 5
JM - Giamaica 5
JO - Giordania 5
NI - Nicaragua 5
PH - Filippine 5
SC - Seychelles 5
BO - Bolivia 4
ET - Etiopia 4
GT - Guatemala 4
PT - Portogallo 4
UY - Uruguay 4
AU - Australia 3
CO - Colombia 3
HN - Honduras 3
IR - Iran 3
KE - Kenya 3
KZ - Kazakistan 3
PY - Paraguay 3
RO - Romania 3
RS - Serbia 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BS - Bahamas 2
CZ - Repubblica Ceca 2
EE - Estonia 2
HR - Croazia 2
KW - Kuwait 2
MK - Macedonia 2
NO - Norvegia 2
QA - Qatar 2
SI - Slovenia 2
SY - Repubblica araba siriana 2
AD - Andorra 1
AM - Armenia 1
BB - Barbados 1
BF - Burkina Faso 1
BY - Bielorussia 1
CD - Congo 1
CM - Camerun 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GF - Guiana Francese 1
GR - Grecia 1
HT - Haiti 1
Totale 8.476
Città #
Ashburn 687
Santa Clara 376
Fairfield 375
Singapore 331
Southend 304
Chandler 259
Woodbridge 236
San Jose 231
Hong Kong 201
Houston 164
Council Bluffs 143
Ann Arbor 130
Seattle 123
Cambridge 117
Nyköping 109
Wilmington 104
Beijing 89
Jacksonville 84
Hefei 82
London 82
Dearborn 78
New York 73
Los Angeles 69
Helsinki 61
Chicago 60
Modena 60
The Dalles 59
Ho Chi Minh City 58
Hanoi 54
Milan 45
Dallas 41
San Diego 40
Seoul 37
Frankfurt am Main 31
Dublin 28
Izmir 27
Princeton 26
Moscow 24
Sofia 24
Shanghai 23
São Paulo 23
Fremont 22
Jakarta 22
Lauterbourg 22
Munich 22
Buffalo 21
Columbus 20
Eugene 19
Brussels 18
Salt Lake City 18
Tokyo 17
Toronto 17
Atlanta 16
Casablanca 16
Cologno Monzese 16
Boardman 15
Naples 14
North Bergen 14
Norwalk 12
Orem 11
San Francisco 11
Denver 10
Des Moines 10
Miami 10
Montreal 10
Phoenix 10
Pisa 10
Johannesburg 9
San Giuliano Milanese 9
San Salvador 9
Bremen 8
Falls Church 8
Lviv 8
Nuremberg 8
Philadelphia 8
Rome 8
Amsterdam 7
Bologna 7
Brusaporto 7
Chongqing 7
Da Nang 7
Haiphong 7
Lima 7
Parma 7
Redondo Beach 7
Saint Augustine 7
Warsaw 7
Boston 6
Brasília 6
Brooklyn 6
Calgary 6
Changsha 6
Contagem 6
Dong Ket 6
Guangzhou 6
Ottawa 6
Quito 6
Redwood City 6
Washington 6
Baghdad 5
Totale 5.800
Nome #
Cell-penetrating CaCO3nanocrystals for improved transport of NVP-BEZ235 across membrane barrier in T-cell lymphoma 412
Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery 410
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 397
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 396
Activity of BKM120 and BEZ235 against lymphoma cells 391
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 370
Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project 348
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 341
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 327
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 310
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma 309
Genomic profiling of enzastaurin-treated B cell lymphoma RL cells 309
Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases 309
Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project 306
Effects of Enzastaurin, Alone or in Combination, on Signalling Pathway Controlling Growth and Survival of B-Cell Lymphoma Cell LinesBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 4978 305
Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines. 303
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts 302
The Oral PKC-ß Inhibitor Enzastaurin (LY317615) Suppress Phosphorylation and Induces Apoptosis in Multiple Myeloma Cell Lines by Inhibition of AKT Pathway. 282
ALK-negative anaplastic large cell lymphoma: Features and outcomes of 235 patients from the International T-Cell Project 272
Molecular targeting of the PKC-β inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression 271
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project 266
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination 256
Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma project 241
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas 232
COVID-related disruption in mammographic screening: a year later. 192
Survival outcomes for extranodal natural-killer T-cell lymphoma – Authors' reply 176
The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network 171
The Value and relevance of T-cell lymphoma registries 162
Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019 86
Clinical outcome and proportion of hereditary cancer genes gPV in TNBC: the HEaRTBeat study. 53
Preparing real-world data through common data model harmonization of cancer patient records in the COMNet platform at the Modena Oncology Center. 37
Totale 8.542
Categoria #
all - tutte 32.552
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.552


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022398 0 0 0 0 9 64 36 22 44 46 107 70
2022/2023648 74 114 44 66 43 95 7 57 88 7 25 28
2023/2024421 18 24 18 50 82 34 43 47 5 17 48 35
2024/20251.230 50 11 36 103 233 179 96 68 120 43 102 189
2025/20262.581 176 84 165 227 323 188 343 145 274 251 261 144
2026/20271.028 179 165 167 399 118 0 0 0 0 0 0 0
Totale 8.542